Physician profile
Timothy Fullagar
NPI 1629088364
$9,626.44
in general payments reported to CMS, 2019-2025
42 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,793 · 2020: $500 · 2021: $1,246 · 2022: $1,279 · 2023: $1,399 · 2024: $1,890 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,809.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,507.63 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Medtronic USA, INC. | $1,479.21 | 2019-2020 | |
| Nevro Corp. | $317.91 | 2019-2024 | Senza |
| Zimmer Biomet Holdings, INC. | $285.17 | 2019-2021 | |
| Depuy Synthes Sales INC. | $196.62 | 2019-2022 | |
| Biocomposites INC | $192.97 | 2024 | |
| Stryker Corporation | $187.37 | 2021-2023 | Spinejack |
| Livanova USA, INC. | $153.72 | 2019 | |
| Spinefrontier, INC. | $100.35 | 2024 | Inspan |
| Arbor Pharmaceuticals, INC. | $95.82 | 2019 | |
| Portola Pharmaceuticals, LLC | $93.81 | 2019-2020 | |
| Innovation Technologies INC | $87.75 | 2024 | Irrisept |
| Abbvie INC. | $69.28 | 2023-2024 | |
| Ucb, INC. | $69.23 | 2021-2022 | |
| Ossur Americas, INC. | $62.12 | 2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Fullagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.